Lyme Disease: Why Patients Are Turning Away from Conventional Medicine
By Holly Ahern, Professor Emerita of Microbiology, Ballston Lake, NY
The medical community’s approach to Lyme disease is failing patients—and it’s time we faced the hard truths. As a researcher dedicated to improving diagnostic tests for Lyme disease, a member of state and federal working groups examining chronic Lyme-related illnesses (https://cdmrp.health.mil/cwg/stories/2020/hollyahernprofile), and the mother of a Lyme disease patient, I’ve witnessed firsthand the gaps in our understanding and treatment of this complex illness. Recently, an opinion piece by a medical student ("The myth, the legend, the truth about chronic Lyme disease," https://www.syracuse.com/opinion/2026/02/the-myth-the-legend-the-truth-about-chronic-lyme-disease-guest-opinion-by-samantha-ballas.html) prompted me to address misconceptions that persist in both medical discourse and public perception.
But here’s where it gets controversial: Lyme disease, caused by a bacterium with a unique life strategy, defies the conventional model of bacterial infections. Despite the widespread belief that current medical guidelines are evidence-based, they often fall short of addressing the disease’s complexities. This one-size-fits-all approach leaves many patients in limbo, forcing them to seek alternative treatments from functional providers. And this is the part most people miss: the guidelines have failed countless individuals over decades, yet they remain the standard.
Let’s start with the legend. Fifty years ago, a Yale researcher identified a previously unknown bacterial infection and named it Lyme disease. Diagnostic tests were developed, and antibiotics became the go-to treatment. However, treatment-resistant cases emerged in nearly half of diagnosed patients, leading to more aggressive antibiotic regimens. Research also uncovered the bacteria’s persistence post-treatment and its transmission during pregnancy, resulting in adverse outcomes. Yet, progress stalled by 2001, and Lyme disease was dismissed as “hard to catch and easy to cure.” This led to a rift between patients and researchers, with patients being unfairly labeled as “Lyme loonies” by an NIH official in 2007. Sadly, this stigmatization persists today.
The reality? With over 500,000 diagnosed cases annually in the U.S., Lyme disease is far from rare. A significant percentage of patients experience persistent, debilitating symptoms lasting months to years, proving it’s not easy to cure either. That’s the truth.
Now, let’s debunk the myths. One pervasive belief is that Lyme disease is easy to diagnose because patients always recall a tick bite and present with a bull’s-eye rash. Early studies claimed over 70% of cases began with this rash—but here’s the catch: those studies relied heavily on the rash for case determination, introducing a glaring bias. Newer research reveals that fewer than half of patients remember a tick bite, 40% report no rash, and only 10% of rashes resemble a bull’s-eye. Not exactly a reliable diagnostic tool.
Diagnostic tests, introduced 40 years ago, have long been acknowledged as inaccurate—yet we still use them. Positive results are often dismissed as false positives, leaving patients untreated, while negative results don’t rule out the disease. Confusing, right?
Symptoms further complicate matters. Women experience Lyme disease differently than men. Men are more likely to develop the bull’s-eye rash, test positive, and exhibit obvious symptoms. Women, however, often present with non-specific symptoms like fatigue, headaches, heart palpitations, vomiting, photophobia, and severe memory loss or psychiatric issues. This disparity means men are treated, while women are frequently referred or misdiagnosed. And this is where it gets even more troubling: late diagnoses, which disproportionately affect women, increase the risk of chronic illness.
Treatment adds another layer of complexity. While a short course of oral antibiotics is recommended, Lyme’s unique bacterium often resists this approach. The claim that additional antibiotic treatment isn’t warranted due to “lack of evidence” ignores the fact that there’s also no evidence it doesn’t work. We simply lack sufficient research.
Here’s the bold truth: We desperately need federally funded, unbiased clinical studies and updated medical school curricula. Until then, patients will continue to suffer, and the divide between medical professionals and those they’re meant to serve will only widen.
Thought-provoking question for you: Should we prioritize funding for Lyme disease research to address these gaps, or is the current approach sufficient? Share your thoughts in the comments—let’s spark a conversation that could change lives.
